Sarangthem Vijaya

Dr. Sarangthem Vijaya

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2020 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
AYAena Yi
Aena Yi
DSDahye Sim
Dahye Sim
YLYoung-Jin Lee
Young-Jin Lee
SVSarangthem Vijaya
Sarangthem Vijaya
RPRang-Woon Park
Rang-Woon Park
Background: The successful deliveries of siRNA depend on their stabilities under physiological conditions because greater in vivo stability enhances cellular uptake and enables endosomal escape. Viral-based systems appears as most efficient approaches for gene delivery but often compromised in terms of biocompatibility, patient safety and high cost scale up process. Here we describe a novel platform of gene delivery by elastin-like polypeptide (ELP) based targeting biopolymers. Results: For better tumor targeting and membrane penetrating characteristics, we designed various chimeric ELP-based carriers containing a cell penetrating peptide (Tat), single or multiple copies of AP1 an IL-4 receptor targeting peptide along with coding sequence of ELP and referred as Tat-A1E28 or Tat-A4V48. These targeted polypeptides were further analyzed for its ability to deliver siRNA (Luciferase gene) in tumor cells in comparison with non-targeted controls (Tat-E28 or E28). The positively charged amino acids of these polypeptides enabled them to readily complex with negatively charged nucleic acids. The complexation of nucleic acid with respective polypeptides facilitated its transfection efficiency as well as stability. The targeted polypeptides (Tat-A1E28 or Tat-A4V48) selectively delivered siRNA into tumor cells in a receptor-specific fashion, achieved endosomal and lysosomal escape, and released gene into cytosol. The target specific delivery of siRNA by Tat-A1E28 or Tat-A4V48 was further validated in murine breast carcinoma 4T1 allograft mice model. Conclusion: The designed delivery systems efficiently delivered siRNA to the target site of action thereby inducing significant gene silencing activity. The study shows Tat and AP1 functionalized ELPs constitute a novel gene delivery system with potential therapeutic applications.

8 March 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SVSarangthem Vijaya
Sarangthem Vijaya
HSHarshita Sharma
Harshita Sharma
RGRidhima Goel
Ridhima Goel
SGSampa Ghose
Sampa Ghose
RPRang-Woon Park
Rang-Woon Park
TSThoudam Debraj Singh
Thoudam Debraj Singh

27 May 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
JHJisan Hong
Jisan Hong
DSDahye Sim
Dahye Sim
BLByung-Heon Lee
Byung-Heon Lee
SVSarangthem Vijaya
Sarangthem Vijaya
RPRang-Woon Park
Rang-Woon Park
Background: The exogenous delivery of miRNA to mimic and restore miRNA-34a activity in various cancer models holds significant promise in cancer treatment. Nevertheless, its effectiveness is often impeded by challenges, including a short half-life, propensity for off-target accumulation, susceptibility to inactivation by blood-based enzymes, concerns regarding patient safety, and the substantial cost associated with scaling up. As a means of overcoming these barriers, we propose the development of miRNA-loaded Tat-A86 nanoparticles by virtue of Tat-A86's ability to shield the loaded agent from external environmental factors, reducing degradation and inactivation, while enhancing circulation time and targeted accumulation. Results: Genetically engineered Tat-A86, featuring 16 copies of the interleukin-4 receptor (IL-4R)-binding peptide (AP1), Tat for tumor penetration, and an elastin-like polypeptide (ELP) for presenting target ligands and ensuring stability, served as the basis for this delivery system. Comparative groups, including Tat-E60 and A86, were employed to discern differences in binding and penetration. The designed ELP-based nanoparticle Tat-A86 effectively condensed miRNA, forming stable nanocomplexes under physiological conditions. The miRNA/Tat-A86 formulation bound specifically to tumor cells and facilitated stable miRNA delivery into them, effectively inhibiting tumor growth. The efficacy of miRNA/Tat-A86 was further evaluated using three-dimensional spheroids of lewis lung carcinoma (LLC) as in vitro model and LLC tumor-bearing mice as an in vivo model. It was found that miRNA/Tat-A86 facilitates effective cell killing by markedly improving miRNA penetration, leading to a substantial reduction in the size of LLC spheroids. Compared to other controls, Tat-A86 demonstrated superior efficacy in suppressing the growth of 3D cellular aggregates. Moreover, at equivalent doses, miRNA-34a delivered by Tat-A86 inhibited the growth of LLC cells in allograft mice. Conclusions: Overall, these studies demonstrate that Tat-A86 nanoparticles can deliver miRNA systemically, overcoming the basic hurdles impeding miRNA delivery by facilitating both miRNA uptake and stability, ultimately leading to improved therapeutic effects. Graphical

22 July 2020 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
SCSun-Ha Cheon
Sun-Ha Cheon
BSBo-Yeon Seo
Bo-Yeon Seo
YLYoung-Jin Lee
Young-Jin Lee
DSDahye Sim
Dahye Sim
SLSeon-Boon Lee
Seon-Boon Lee
RPRang-Woon Park
Rang-Woon Park

13 February 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
RGRidhima Goel
Ridhima Goel
DGDeepak Gulwani
Deepak Gulwani
PUPriyanka Upadhyay
Priyanka Upadhyay
SVSarangthem Vijaya
Sarangthem Vijaya
TSThoudam Debraj Singh
Thoudam Debraj Singh

17 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
SVSarangthem Vijaya
Sarangthem Vijaya
HSHarshita Sharma
Harshita Sharma
MMMohini Mendiratta
Mohini Mendiratta
RSRanjit Kumar Sahoo
Ranjit Kumar Sahoo
RPRang-Woon Park
Rang-Woon Park
SMSujata Mohanty
Sujata Mohanty
Regenerative medicine using stem cells offers promising strategies for treating a variety of degenerative diseases. Regulation of stem cell behavior and rejuvenate senescence are required for stem cells to be clinically effective. The extracellular matrix (ECM) components have a significant impact on the stem cell’s function and fate mimicking the local environment to maintain cells or generate a distinct phenotype. Here, human elastin-like polypeptide-based ECM-mimic biopolymer was designed by incorporating various cell-adhesion ligands, such as RGD and YIGSR. The significant effects of bioactive fusion ELPs named R-ELP, Y-ELP, and RY-ELP were analyzed for human bone-marrow-derived stem cell adhesion, proliferation, maintenance of stemness properties, and differentiation. Multivalent presentation of variable cell-adhesive ligands on RY-ELP polymers indeed promote efficient cell attachment and proliferation of human fibroblast cells dose-dependently. Similarly, surface modified with RY-ELP promoted strong mesenchymal stem cell (MSCs) attachment with greater focal adhesion (FA) complex formation at 6 h post-incubation. The rate of cell proliferation, migration, population doubling time, and collagen I deposition were significantly enhanced in the presence of RY-ELP compared with other fusion ELPs. Together, the expression of multipotent markers and differentiation capacity of MSCs remained unaffected, clearly demonstrating that stemness properties of MSCs were well preserved when cultured on a RY-ELP-modified surface. Hence, bioactive RY-ELP offers an anchorage support system and effectively induces stimulatory response to support stem cell proliferation.